The clarithromycin resistency of H. Pylori within peptic south-west hungarian patients

Aims: H. pylori antibiotic resistency strongly influence the success of eradication therapy – with all its socio-biological and cost effectiveness aspects. Clarithromycin is a widely used antibiotic in anti-Helicobacter protocols. Recent study we planned to investigate clarithromycin resistency's uprunning prevalence after a decade of its widespread use in South-West Hungary.

Patients, method and results: We examined 69 patients' consequtive (pts) H. pylori positive biopsy samples in 3 subgroups. Creafast in situ hibridisation method was used for proveing clarithromycin resistency. Male/female ratio was 28/41, the everage age was 56.9 years and the resistant pts were 21.7%. In 3 cases we had mixed population.

	Resistent (N=15)	Sensitive (N=51)
Duodenal ulcer (UD) 25 pts	10	14
Gastric ulcer (GU) 18 pts	1	17
H.p. assoc. gastritis 26 pts	4	20

Conclusion: Remarkable number (18/69–26%) of peptic pts' biopsy samples have presented clarithromycin resistent Helicobacteri. The largest proportion we observed in the UD subgroup. Because of the high incidence of clarithromycin resistency in this region one has to take in consideration not to involve Clarithromycin in the second eradication protocol. Creafast is suggested to use in samples of H. pylori positive high risk patients, who had been undergone one unsuccesful eradication therapy.